1.Long-Term Effectiveness and Safety of Dutasteride versus Finasteride in Patients with Male Androgenic Alopecia in South Korea: A Multicentre Chart Review Study
Gwang-Seong CHOI ; Woo-Young SIM ; Hoon KANG ; Chang Hun HUH ; Yang Won LEE ; Sumitra SHANTAKUMAR ; Yu-Fan HO ; Eun-Jeong OH ; Mei Sheng DUH ; Wendy Y. CHENG ; Priyanka BOBBILI ; Philippe THOMPSON-LEDUC ; Gary ONG
Annals of Dermatology 2022;34(5):349-359
Background:
Dutasteride improves hair growth compared with finasteride in male androgenic alopecia (AGA) and is well tolerated. However, real-world evidence for longterm dutasteride use in AGA is lacking.
Objective:
To describe baseline characteristics, treatment patterns and long-term safety and effectiveness of dutasteride versus finasteride.
Methods:
This was a multicentre, retrospective medical chart review study conducted in South Korea. The index date was the first prescription of dutasteride or finasteride. Baseline characteristics were assessed 6 months prior to index. Safety and effectiveness improvements in basic and specific [BASP] classification) data were collected from index throughout the observation period.
Results:
Overall, 600 male adult patients were included (dutasteride, n=295; finasteride, n=305). Dutasteride-treated patients were older (p<0.001) and more likely to have moderate/ severe BASP classification at baseline (p=0.010) compared with finasteride-treated patients. Among patients treated with recommended, on-label dosing exclusively (n=535: dutasteride, n=250; finasteride, n=285), dutasteride-treated patients showed greater improvement in hair growth than finasteride-treated patients, as measured by the BASP basic M classification (adjusted incidence rate ratio [95% confidence interval]: 2.06 [1.08, 3.95]; p=0.029). Among this same subset, overall occurrence of adverse events (AEs) during the observation period were not statistically equivalent between groups (dutasteride 7.6%, finasteride 10.5%; p=0.201), although reports of AEs of special interest were equivalent (p<0.001).
Conclusion
Dutasteride showed greater effectiveness than finasteride in improving BASP classification in treating male AGA and had a similar or possibly lower occurrence of overall AEs. Dutasteride may provide an effective and safe treatment option for male patients with AGA.
2.Change in hair growth-related gene expression profile in human isolated hair follicles induced by 5-alpha reductase inhibitors - dutasteride and finasteride - in the presence of testosterone.
Toshiki HATANAKA ; Zrinka LULIC ; Tim MEFO ; Cath BOOTH ; Elliott HARRISON ; Gary ONG
Singapore medical journal 2022;63(9):552-558